ZIOPHARM Oncology

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Co ntinues to Execute on Strategy to Ensure Strong Long-Term Outlook

Ziopharm Releases Investor Presentation Highlighting Execution of Strategy and Substantial Board Refreshment to Enhance Shareholder Value

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today released a 55-page presentation that details the case for urgent change in the boardroom and summarizes its director candidates' value-enhancing vision. As a reminder, W

WaterMill Asset Management Releases Presentation Detailing the Case for Urgent Change Atop Ziopharm Oncology

– First Data from Ongoing Phase 2 Study of Controlled IL-12 in Combination with Cemiplimab Demonstrate Promising Safety Profile in rGBM,  and a Confirmed Partial Response –

Ziopharm Oncology Presents Encouraging Clinical Data for Controlled IL-12 for the Treatment of Glioblastoma and DIPG at the 2020 Society for Neuro-Oncology Annual Meeting

– Pharmaceutical Executive with 2 0 + Year s of Experience Across All Phases of Clinical Research Including IND Submission s , Trial Design and Regulatory Filings –

Ziopharm Oncology Appoints Raffaele Baffa, M.D., Ph.D., as Chief Medical Officer

– Special Advisor and Former Chief of Staff for the Bill & Melinda Gates Medical Research Institute Joins as Independent Director –

Ziopharm Oncology Appoints Mary Thistle to Board of Directors

BOSTON, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020 at 1:45 pm ET.

Ziopharm Oncology to Participate in Jefferies Virtual London Healthcare Conference on November 19, 2020

CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Level One Partners, LLC, (“Level One Partners”) along with all of its related entities, will vote 100% of its approximately 10.68 million shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) in support of the WaterMill Asset Management Corp. proposal for a reconstituted Board of Directors and significant changes to the governance of the Company. Level One Partners' 10.68 million shares equal approximately 4.98% of the Company's ou

Level One Partners Supports Watermill's Proposal for Ziopharm Oncology

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q3 2020 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below letter to shareholders in support of the proposals included in its definitive consent statement filed with the U.S. Securities and Exchange Commission o

WaterMill Asset Management Sends Letter to Ziopharm Oncology Shareholders

Urges Shareholders to Sign and Return Ziopharm's GREEN Consent Revocation Card

Ziopharm Files Definitive Consent Revocation Statement and Sends Letter to Shareholders

NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”), which collectively with the other participants in its consent solicitation beneficially owns approximately 3.3% of the outstanding shares of Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”), today issued the below statement in connection with its filing of a definitive consent statement and accompanying WHITE consent card with the U.S. Securities and Exchange Comm

WaterMill Asset Management Launches Consent Solicitation to Reconstitute the Board of Directors of Ziopharm Oncology

BOSTON, Oct. 16, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced that it has received a notice, and acknowledges the filing of, a preliminary consent solicitation statement by WaterMill Asset Management Corp., Mr. Robert W. Postma and affiliated parties who together report to own 7,173,650 shares of Ziopharm, stating they intend to solicit the written consent of stockholders to remove without cause four members of the Company's Board of Directors, amend several bylaws and elect the three individuals to the Company's Board of Directors, including Mr. Postma himself. The Company has issued the following statement commenting on the notice:

Ziopharm Oncology Announces Receipt of Shareholders' Intent to Solicit Written Consents

BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced that Laurence Cooper, M.D., Ph.D., Chief Executive Officer of Ziopharm, is scheduled to participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Virtual Summit on October 5, 2020 at 12:30 pm ET.

Ziopharm Oncology to Participate in Jefferies Cell Therapy Virtual Summit on October 5, 2020

Banco BBVA Argentina SA

EuroDry Ltd

Allspring Global Dividend Opportunity Fund

Gen Digital Inc

This month's collection of penny stocks has little in common beyond rock-bottom prices and promising technical chart patterns.

Penny Stocks to Buy Using Technical Analysis for October 2020

– Life Sciences industry veteran; 15-year Cephalon executive, serving progressively   as CFO, COO and then CEO at time of $6.8 billion acquisition by Teva –

Ziopharm Oncology Appoints Kevin Buchi to its Board of Directors

BOSTON, Sept.  15, 2020  (GLOBE NEWSWIRE) --  Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP), today announced the appointment of four additional members to its Scientific Advisory Board (SAB). The SAB, under the leadership of Carl June, M.D. as chairman, will provide strategic and scientific counsel to guide development of Ziopharm’s pipeline of immunotherapies to treat patients with solid tumors.

Ziopharm Oncology Appoints Four Additional Members to Scientific Advisory Board

One of the biotech's pipeline candidates won a key FDA designation.

Why Ziopharm Oncology Shares Zoomed Higher Today

BOSTON, Sept.  14, 2020  (GLOBE NEWSWIRE) --  Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the investigational treatment of diffuse intrinsic pontine glioma (DIPG), a lethal brain tumor occurring in the pontine region of the brain. DIPG accounts for approximately 10 to 15 percent of all cases of brain tumors in children. The Rare Pediatric Disease Designation program is intended to encourage the development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.

Ziopharm Oncology Granted Rare Pediatric Disease Designation for Controlled IL-12 for the Treatment of DIPG

ZIOPHARM Oncology, Inc. (ZIOP) CEO Laurence Cooper on Q2 2020 Results - Earnings Call Transcript

BOSTON, July  28, 2020  (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP), today announced the Company will host a conference call and webcast on Thursday, August 6, at 4:30 pm EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2020.

Ziopharm Oncology to Report Second Quarter 2020 Financial Results and Host a Conference Call and Webcast on August 6, 2020

– Industry veteran entrepreneur with 20+ years’ experience founding and financing successful, innovative biotech companies including GenScript and Legend Biotech –

Ziopharm Oncology Names James Huang to Board of Directors

- RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer - - RPM leverages the Sleeping Beauty system to reduce cost and simplify production for CD19-specific CAR-T infusion the day after gene transfer -

Ziopharm Oncology Announces Initiation of Phase 1 Trial Evaluating Rapid Personalized Manufacturing CAR-T Technology in Patients with Relapsed CD19+ Leukemias and Lymphomas

BOSTON, July  08, 2020  (GLOBE NEWSWIRE) --  Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that the first patient with diffuse intrinsic pontine glioma (DIPG) has been dosed in its phase 1/2 study of Ad-RTS-hIL-12 with veledimex (Controlled IL-12) for the treatment of pediatric brain tumors.

Ziopharm Oncology Doses First DIPG Patient in Phase 1/2 Trial of Controlled IL-12 for the Treatment of Pediatric Brain Tumors

BOSTON, June  22, 2020  (GLOBE NEWSWIRE) --  Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced that 36 subjects have been enrolled in the phase 2 clinical trial evaluating Ad-RTS-hIL-12 with veledimex (Controlled IL-12) in combination with the PD-1 inhibitor Libtayo® (cemiplimab-rwlc) for the treatment of recurrent or progressive glioblastoma (rGBM) in adults. Subjects in this multi-center trial were enrolled from seven hospitals specializing in the treatment of brain cancers across the United States.

Ziopharm Oncology Completes Enrollment of Phase 2 Trial Evaluating Controlled IL-12 in Combination with Libtayo® in Patients with Glioblastoma

Investors need to pay close attention to Ziopharm Oncology (ZIOP) stock based on the movements in the options market lately.

News for ZIOPHARM Oncology Stock (ZIOP)